Irene Galan-Pastor

Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Journal: Leukemia

Published: January 23, 2026

Copy-Neutral Loss of Heterozygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Copy-Neutral Loss of Heterozygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Journal: The Journal of molecular diagnostics : JMD

Published: September 09, 2025

Copy-Neutral Loss of Heterzygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Copy-Neutral Loss of Heterzygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Journal: The Journal of molecular diagnostics : JMD

Published: September 09, 2025

Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia.

Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia.

Journal: HemaSphere

Published: September 04, 2025

Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling.

Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling.

Journal: Blood advances

Published: August 04, 2025

Patterns of immune recovery after axicabtagene ciloleucel for aggressive B-cell lymphoma.

Patterns of immune recovery after axicabtagene ciloleucel for aggressive B-cell lymphoma.

Journal: HemaSphere

Published: May 14, 2025

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Journal: Blood cancer journal

Published: December 15, 2024

Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR-T Therapy.

Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR-T Therapy.

Journal: EJHaem

Published: November 18, 2024

Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.

Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.

Journal: Leukemia

Published: July 12, 2024

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Journal: Leukemia

Published: June 19, 2024

EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.

EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.

Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology

Published: December 17, 2023

Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.

Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.

Journal: HemaSphere

Published: February 06, 2023

Showing 1-12 of 19

Last Updated: 09/26/2026